Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase1 Randomized, Double-Blind, Placebo/Active-Controlled, SAD, 2-Way, Incomplete Block, 2-Period Crossover, Safety, Tolerability, PK/PD Study of 3 Doses INP105 (Olanzapine Delivered by I231 POD Device) Nasal Spray in Healthy Volunteers

Next Previous
Search
Trial Profile

Phase1 Randomized, Double-Blind, Placebo/Active-Controlled, SAD, 2-Way, Incomplete Block, 2-Period Crossover, Safety, Tolerability, PK/PD Study of 3 Doses INP105 (Olanzapine Delivered by I231 POD Device) Nasal Spray in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary) ; Olanzapine; Olanzapine
  • Indications Agitation
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms SNAP101
  • Sponsors Impel Pharmaceuticals

    • Most Recent Events

    • 30 Jun 2020 Results presented in an Impel NeuroPharma media release.
    • 30 Jun 2020 According to an Impel NeuroPharma media release, the data from this study is been published in the The Journal of Clinical Psychiatry.
    • 23 May 2019 According to an Impel NeuroPharma media release, data from the study were presented at the American Psychiatric Association (APA) Annual Meeting 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top